

Open Peer Review on Qeios

Gefitinib

National Cancer Institute

Source

National Cancer Institute. <u>Gefitinib</u>. NCI Thesaurus. Code C1855.

An anilinoquinazoline with antineoplastic activity. Gefitinib inhibits the catalytic activity of numerous tyrosine kinases including the epidermal growth factor receptor (EGFR), which may result in inhibition of tyrosine kinase-dependent tumor growth. Specifically, this agent competes with the binding of ATP to the tyrosine kinase domain of EGFR, thereby inhibiting receptor autophosphorylation and resulting in inhibition of signal transduction. Gefitinib may also induce cell cycle arrest and inhibit angiogenesis. (NCI04)

Qeios ID: PY4SEP · https://doi.org/10.32388/PY4SEP